Clinical Trial

Video Game Play to Alleviate Adolescent Anxiety

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated May 23, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Adolescence is a critical period for the onset and maintenance of anxiety disorders, which raises the importance of intervening early; one possibility of doing so is via digital interventions. At least two lines of research have been explored in the past years in this area. First, studies have tested the anxiolytic effects of casual video games, hypothesizing that, through the induction of flow, these games can effectively distract individuals from anxiety-related thoughts and feelings. Second, the bidirectional link between poor attentional control and higher anxiety has led to the design of novel interventions aiming to improve attentional control such as working memory training studies. Importantly, action video games, classified as a distinct gaming genre, have been shown to enhance attentional control. In this study, we aim to compare the effects of action video game play and casual game play to a no-training group, assessing their potential to alleviate anxiety when delivered entirely online. The goal of this three- arms randomized controlled trial is to evaluate the feasibility of a 6-week video game training intervention to reduce adolescent anxiety-related symptoms. We will also examine the efficacy of the proposed treatment when entirely deployed at adolescents' home.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-20; most recent amendment 2025-05-20.
Status change: Not Yet Recruiting → Recruiting 2025-05-20
Trial Details
NCT Number NCT05923944
Lead Sponsor School of Health Sciences Geneva
Collaborators: University of Geneva, Switzerland, University of Haifa, Swiss National Science Foundation
Conditions Anxiety, Anxiety Disorders and Symptoms
Enrollment 150 participants
Start Date 2024-06-01
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-05-23